DISORDERS OF THE RESPIRATORY SYSTEM PART 3.2 (based on T) Flashcards

1
Q

What is the indication for corticosteroids in COVID-19?

A

Patients classified as severe & critical COVID-19.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the dosing regimen for IV dexamethasone in COVID-19?

A

0.15 mg/kg IV once daily (max dose: 6mg) for up to 10 days or until discharge.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the alternative IV corticosteroids if dexamethasone is unavailable?

A

Methylprednisolone: 0.8 mg/kg IV once daily (max dose: 32mg) OR Hydrocortisone based on age-specific dosing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the dosing regimen for oral corticosteroids in COVID-19?

A

Dexamethasone PO: 0.15 mg/kg orally once daily (max dose: 6mg) OR Prednisolone: 1 mg/kg orally once daily (max dose: 40mg).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the contraindications for corticosteroids?

A

Systemic fungal infection, systemic infection unless treated, hypersensitivity to the active ingredient or any component.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the adverse effects of corticosteroids?

A

Adrenal suppression, immunosuppression, hyperglycemia, psychiatric disturbances, hypertension, edema, myopathy, hypernatremia, avascular necrosis, adrenal insufficiency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the indication for Tocilizumab in COVID-19?

A

Patients with rapid respiratory deterioration requiring high oxygen and with elevated inflammation markers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the dosing regimen for Tocilizumab in COVID-19?

A

8 mg/kg (≥30 kg) or 12 mg/kg (<30 kg) as a single dose (max: 800 mg). A second dose may be given ≥8 hours after if no improvement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the contraindications for Tocilizumab?

A

Hypersensitivity to Tocilizumab or any component of the formulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are precautions for Tocilizumab use?

A

Immunocompromised patients, ALT >5x ULN, high GI perforation risk, uncontrolled serious infections, ANC <500, platelets <50,000.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the adverse effects of Tocilizumab?

A

Serious infections (TB, opportunistic), increased cholesterol, constipation, neutropenia, elevated AST/ALT, injection/infusion site reactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the indication for Bamlanivimab + Etesevimab in COVID-19?

A

Child, non-hospitalized, lab-confirmed SARS-CoV-2, mild-moderate COVID-19, within 10 days of symptoms, high risk for severe disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the dosing regimen for Bamlanivimab + Etesevimab?

A

IV infusion based on weight: 1-12 kg: 12 mg/kg Bamlanivimab + 24 mg/kg Etesevimab, ≥40 kg: 700 mg Bamlanivimab + 1400 mg Etesevimab.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the contraindications for Bamlanivimab + Etesevimab?

A

Severe hypersensitivity (e.g., anaphylaxis) to Bamlanivimab, Etesevimab, or any component.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the adverse effects of Bamlanivimab + Etesevimab?

A

Fever, chills, dizziness, dyspnea, urticaria, pruritus, flushing, nausea, vomiting.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the indication for Casirivimab + Imdevimab in COVID-19?

A

Child/adolescent >12 years, >40 kg, non-hospitalized, lab-confirmed SARS-CoV-2, mild-moderate COVID-19, within 10 days of symptoms, high risk for severe disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the dosing regimen for Casirivimab + Imdevimab?

A

600 mg Casirivimab + 600 mg Imdevimab as a single IV infusion over ≥60 minutes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the contraindications for Casirivimab + Imdevimab?

A

Severe hypersensitivity (e.g., anaphylaxis) to Casirivimab, Imdevimab, or any component.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the adverse effects of Casirivimab + Imdevimab?

A

Fever, chills, dizziness, dyspnea, urticaria, pruritus, flushing, nausea, vomiting.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the US NIH recommendation for mAb therapy in regions with Omicron VOC?

A

If Delta VOC is still prevalent, Bamlanivimab + Etesevimab or Casirivimab + Imdevimab may be used, but they are ineffective against Omicron.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the recommended monoclonal antibody for Omicron VOC?

A

Sotrovimab should be administered within 10 days of symptom onset in patients ≥12 years and ≥40 kg.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Is Sotrovimab available in the Philippines?

A

No, Sotrovimab is not yet available in the Philippines.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the recommended dosing regimen for methylprednisolone in MIS-C?

A

1-2 mg/kg/dose (max: 30 mg/dose) IV q12h initially, then shift to oral corticosteroids once defervescence occurs or after 3-5 days, tapered off over 3-4 weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

When is high-dose pulse glucocorticoids recommended in MIS-C?

A

In patients who do not respond to IVIG and low-dose corticosteroids, especially those on high-dose multiple inotropes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the contraindications for corticosteroids in MIS-C?

A

Systemic fungal infection, systemic infection unless specific anti-infective therapy is employed, hypersensitivity to the active ingredient or any component.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What are the major adverse effects of corticosteroids in MIS-C?

A

Adrenal suppression, immunosuppression (reactivation of latent infections, secondary infections), hyperglycemia, psychiatric disturbances, increased blood pressure, peripheral edema, myopathy, hypernatremia, avascular necrosis, adrenal insufficiency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the recommended dosing regimen for IVIG in MIS-C?

A

2 g/kg over 8-12 hours (max 100 g); assess cardiac function and fluid status before administration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are the contraindications for IVIG in MIS-C?

A

History of anaphylaxis to human Ig, IgA deficient patients with antibodies against IgA and a history of hypersensitivity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the major adverse effects of IVIG in MIS-C?

A

Hypersensitivity reaction (including anaphylaxis), infusion reactions (headache, chills, myalgia, wheezing, tachycardia, lower back pain, nausea, hypotension), renal failure, thromboembolism, aseptic meningitis syndrome, hemolysis, transfusion-related acute lung injury, transmission of infectious pathogens.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is the recommended dosing regimen for anticoagulation in MIS-C?

A

ASA 3-5 mg/kg/dose (max: 81 mg/dose) PO OD until platelet count normalizes and normal coronary arteries are confirmed at ≥ 4 weeks after diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What additional anticoagulation is recommended for severe MIS-C cases?

A

MIS-C patients with a coronary aneurysm z-score ≥10.0, ejection fraction <35%, or documented thrombosis should receive low-dose aspirin and therapeutic anticoagulation with enoxaparin; consult Cardiology and Hematology.

32
Q

What are the contraindications for anticoagulation in MIS-C?

A

Platelet count <100,000/μL, active bleeding, or significant bleeding risk.

33
Q

What is the US CDC case definition for MIS-C?

A

An individual <21 years old presenting with fever, laboratory evidence of inflammation, and clinically severe illness requiring hospitalization with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological); AND no alternative plausible diagnoses; AND positive for current or recent SARS-CoV-2 infection or exposure within 4 weeks prior to symptom onset.

34
Q

What are the additional comments on MIS-C diagnosis?

A

Some individuals may meet full or partial Kawasaki disease criteria but should still be reported if they meet MIS-C criteria. Consider MIS-C in any pediatric death with SARS-CoV-2 infection.

35
Q

What are the mask recommendations for children in MIS-C?

A

Children <2 years old should NOT wear masks due to suffocation risk. Masks are not recommended for those with difficulty breathing, cognitive/respiratory impairment, or if masks increase face touching.

36
Q

What are hygiene recommendations for children with MIS-C?

A

Proper hand washing with soap and water for 20 seconds should be performed before/after contact, after handling secretions, before/after feeding, after using the toilet, and if hands are visibly dirty.

37
Q

What are the recommended precautions for caregivers of children with MIS-C?

A

Assign one caregiver in good health with no comorbidities. Caregivers should wear a surgical mask, use gloves for handling secretions, and practice hand hygiene.

38
Q

What are key sanitation practices for children with MIS-C?

A

Avoid direct contact with secretions and stool. Flush toilets with the lid down. Disinfect frequently touched surfaces with household soap or detergent.

39
Q

What are laundry and waste disposal guidelines for children with MIS-C?

A

Do not shake dirty laundry. Wash separately with warm water and detergent. Dispose of waste (diapers, tissues) in a sealed bin. Wear gloves and masks when handling soiled items.

40
Q

What are the current recommendations for home therapies in MIS-C?

A

Paracetamol for fever relief. Avoid nebulization unless indicated. Antibiotics per physician’s discretion. Emphasize balanced diet, hydration, and vitamin intake.

41
Q

What are the emotional and mental support recommendations for children with MIS-C?

A

Talk to the child about their condition in a reassuring way. Limit exposure to news and social media. Maintain routine, allow learning and play, and limit screen time.

42
Q

What are the monitoring guidelines for children with MIS-C at home?

A

Caregivers should record symptoms and notify healthcare providers if symptoms worsen or if close contacts develop symptoms. Seek hospital care if no improvement in 2-3 days.

43
Q

Who should be admitted and tested for COVID-19?

A

All patients with moderate, severe, or critical symptoms should be admitted, assumed to have COVID-19, and tested.

44
Q

What should be done if a facility cannot handle COVID-19 patients?

A

Referral to a COVID-19 referral center must be done.

45
Q

Where should a child with moderate to severe COVID-19 symptoms be placed in the hospital?

A

In an isolation room or a dedicated COVID-19 ward/floor.

46
Q

What personal protective equipment (PPE) should a healthcare worker wear when handling a COVID-19 patient?

A

Cap, N95 mask, goggles, face shield, full impermeable gown, gloves, and shoe covers.

47
Q

What is the preferred method for diagnosing SARS-CoV-2 infection?

A

Reverse transcriptase polymerase chain reaction (RT-PCR).

48
Q

What specimens are appropriate for RT-PCR testing?

A

Upper (pharyngeal swabs, nasal swabs, nasopharyngeal secretions) and/or lower airway samples (sputum, airway secretions, bronchoalveolar lavage fluid).

49
Q

What is the Department of Health’s recommendation for specimen collection?

A

Collection of both nasopharyngeal and oropharyngeal specimens.

50
Q

What type of specimen has the highest RT-PCR positivity rate in COVID-19 patients?

A

Bronchoalveolar lavage specimens (93%).

51
Q

What was the RT-PCR positivity rate for nasal swabs in a study by Wang et al.?

52
Q

What was the RT-PCR positivity rate for pharyngeal swabs in a study by Wang et al.?

53
Q

Which specimens did not test positive for SARS-CoV-2 in the study by Wang et al.?

A

Urine specimens.

54
Q

What is the estimated peak of viral shedding for SARS-CoV-2?

A

3 to 5 days after the onset of disease.

55
Q

What is the median duration of viral RNA detection in COVID-19 patients?

56
Q

What is the longest observed duration of viral shedding in survivors?

57
Q

When should respiratory specimens be collected in suspected COVID-19 cases?

A

As soon as possible once a suspect case is identified, regardless of symptom onset timing.

58
Q

What should be done if initial RT-PCR testing is negative but suspicion for COVID-19 remains?

A

Resampling and testing from multiple respiratory tract sites is recommended.

59
Q

How does the sensitivity of RT-PCR change over time after exposure?

A

0% on day 1, 33% before symptom onset, 62% on symptom onset day, peaks at 80% on day 3 of symptoms, and declines to 34% by day 21.

60
Q

What should always be included in the differential diagnosis for a patient with fever and respiratory symptoms?

61
Q

What type of antibodies can be detected after SARS-CoV-2 infection?

A

IgM and IgG.

62
Q

What is the sensitivity of IgG/IgM serologic testing within the first 7 days of exposure?

63
Q

What is the highest reported sensitivity of IgG/IgM serologic testing?

A

96% at 21 to 35 days post-exposure.

64
Q

Which serologic test method has the highest pooled sensitivity?

A

Chemiluminescence immunoassay (CLIA) at 97.8%.

65
Q

What is a common finding in the complete blood count (CBC) of children with COVID-19?

A

Lymphopenia with a median absolute lymphocyte count of 1,201 cells/uL.

66
Q

What inflammatory markers are elevated in severe COVID-19?

A

Procalcitonin, D-dimer, and interleukin-6.

67
Q

What oxygen saturation (SpO2) level suggests pneumonia in COVID-19 patients?

68
Q

What SpO2 level suggests severe pneumonia?

69
Q

Why should dengue serologic tests be interpreted with caution in COVID-19 patients?

A

There have been reported cases of false-positive dengue NS1 and serology in confirmed COVID-19 patients.

70
Q

What is the first-line imaging modality for pediatric COVID-19 patients with respiratory symptoms?

A

Chest X-ray.

71
Q

What are typical chest X-ray findings in pediatric COVID-19?

A

Bilateral peripheral and/or subpleural ground glass opacities and/or consolidation.

72
Q

What imaging modality is not recommended as an initial diagnostic test for pediatric COVID-19?

A

Chest CT scan.

73
Q

What are typical chest CT findings in pediatric COVID-19?

A

Bilateral, peripheral and/or subpleural ground glass opacities and/or consolidation in a lower lobe predominant pattern.

74
Q

What imaging modality can be used as an alternative to chest X-ray and CT scan in COVID-19 diagnosis?

A

Chest ultrasound.

75
Q

What are common ultrasound findings in COVID-19 pneumonia?

A

Thickened pleural line, B lines, multifocal consolidations, and pleural line irregularities.

76
Q

What should be done before using investigational drugs in children?

A

Obtain informed consent from parents or legal guardians.